Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
View/ Open
Date
2016-04-05ICR Author
Author
Barry, GS
Cheang, MC
Chang, HL
Kennecke, HF
Type
Journal Article
Metadata
Show full item recordAbstract
A prospective study was conducted to identify biomarkers associated with resistance to panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Patients with previously treated, codon 12/13 KRAS wt, mCRC were prospectively administered panitumumab 6 mg/kg IV q2weeks. Of 34 panitumumab-treated patients, 11 (32%) had progressive disease at 8 weeks and were classified as non-responders. A Nanostring nCounter-based assay identified a 5-gene expression signature (ERBB2, MLPH, IRX3, MYRF, and KLK6) associated with panitumumab resistance (P = 0.001). Immunohistochemistry and in situ hybridization determined that the HER2 (ERBB2) protein was overexpressed in 4/11 non-responding and 0/21 responding cases (P = 0.035). Two non-responding tumors had ERBB2 gene amplification only, and one demonstrated both ERBB2 amplification and mutation. A non-codon 12/13 KRAS mutation occurred in one panitumumab-resistant patient and was mutually exclusive with ERBB2/HER2 abnormalities. This study identifies a 5-gene signature associated with non-response to single agent panitumumab, including a subgroup of non-responders with evidence of aberrant ERBB2/HER2 signaling. KRAS wt tumors resistant to EGFRi may be identified by gene signature analysis, and the HER2 pathway plays an important role in resistance to therapy.
Collections
Subject
Humans
Colorectal Neoplasms
Receptor, erbB-2
Antineoplastic Agents
Antibodies, Monoclonal
Prospective Studies
Genomics
Drug Resistance, Neoplasm
Aged
Female
Male
Proto-Oncogene Proteins p21(ras)
Panitumumab
Research team
Genomic Analysis – Clinical Trials
Language
eng
Date accepted
2016-01-29
License start date
2016-04
Citation
Oncotarget, 2016, 7 (14), pp. 18953 - 18964
Publisher
IMPACT JOURNALS LLC